Literature DB >> 28805590

Nonmotor Fluctuations in Parkinson's Disease.

Christiana Franke1, Alexander Storch2.   

Abstract

The advanced stage of Parkinson's disease (PD) is characterized by motor complications such as motor fluctuations and dyskinesias induced by long-term levodopa treatment. Recent clinical research provides growing evidence that various nonmotor symptoms such as neuropsychiatric, autonomic, and sensory symptoms (particularly pain) also show fluctuations in patients with motor fluctuations (called nonmotor fluctuations or NMF). However, NMF have not yet been adequately considered in routine care of advanced PD patients and only few therapeutic studies are available. Since the pathophysiology of NMF remains largely unknown, innovative therapeutic concepts are largely missing. The close connection of NMF and motor fluctuations, however, strongly suggests that the strategies used to treat motor complications-namely continuous dopaminergic stimulation-also apply for the therapy of NMF. Future controlled clinical trials specifically addressing NMF are urgently warranted.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nonmotor assessment; Nonmotor fluctuations; Nonmotor symptoms; Parkinson's disease; Pathophysiology; Treatment

Mesh:

Year:  2017        PMID: 28805590     DOI: 10.1016/bs.irn.2017.05.021

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  6 in total

1.  Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.

Authors:  Heinz Reichmann; Andrew Lees; José-Francisco Rocha; Diogo Magalhães; Patrício Soares-da-Silva
Journal:  Transl Neurodegener       Date:  2020-03-04       Impact factor: 8.014

2.  The Parkinson fatigue scale: an evaluation of its validity and reliability in Greek Parkinson's disease patients.

Authors:  Ioannis E Dagklis; Efthymia Tsantaki; Dimitrios Kazis; Varvara Theodoridou; Sotirios Papagiannopoulos; Dimitrios Ntantos; Sevasti Bostantjopoulou
Journal:  Neurol Sci       Date:  2019-01-08       Impact factor: 3.307

3.  Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson's disease model.

Authors:  Liyan Hou; Fuqiang Sun; Ruixue Huang; Wei Sun; Dan Zhang; Qingshan Wang
Journal:  Redox Biol       Date:  2019-02-08       Impact factor: 11.799

4.  Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.

Authors:  Heinz Reichmann; Andrew Lees; José-Francisco Rocha; Diogo Magalhães; Patrício Soares-da-Silva
Journal:  Transl Neurodegener       Date:  2020-03-04       Impact factor: 8.014

5.  Triggers and alleviating factors for fatigue in Parkinson's disease.

Authors:  Iris Lin; Briana Edison; Sneha Mantri; Steven Albert; Margaret Daeschler; Catherine Kopil; Connie Marras; Lana M Chahine
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

6.  Pain-Related Abnormal Neuronal Synchronization of the Nucleus Accumbens in Parkinson's Disease.

Authors:  Kaoru Kinugawa; Tomoo Mano; Yuya Yamatani; Toshiteru Miyasaka; Hiroshi Kataoka; Kazuma Sugie
Journal:  Brain Sci       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.